Related by context. All words. (Click for frequent words.) 71 recurrent glioblastoma multiforme 71 relapsing remitting MS RRMS 71 fallopian tube cancers 71 papillary renal cell carcinoma 71 CIMZIA TM certolizumab pegol 71 metastatic GIST 71 biliary tract cancer 70 recurrent metastatic 70 naïve HCV 70 HCV RESPOND 2 70 relapsed MM 70 symptomatic BPH 70 treatment naive genotype 70 CYT# potent vascular disrupting 69 LHRH receptor positive 69 recurrent glioma 69 metastatic malignant melanoma 69 phase IIb clinical 69 recurrent glioblastoma 69 MAGE A3 ASCI 69 Phase IIIb clinical 69 metastatic pancreatic 69 chemoradiation therapy 69 randomized Phase IIb 68 cisplatin gemcitabine 68 relapsed refractory multiple myeloma 68 INSPIRE Trial Phase III 68 dose escalation clinical 68 kidney urologic 68 stage IIIb IV 68 Phase Ib II 68 Carotid Revascularization Endarterectomy vs. 68 BRIM3 68 metastatic bladder 68 ZACTIMA 68 placebo controlled clinical 68 psoriatic arthritis PsA 68 agalsidase alfa 68 multicenter Phase II 68 Vicinium TM 68 resectable pancreatic cancer 68 galiximab 68 novel VDA molecule 68 Combination REOLYSIN R 68 metastatic gastric 68 catheter occlusion 68 evaluating tivozanib 68 oral deforolimus 68 phase IIb study 68 keloid scarring 68 metastatic malignant 68 lintuzumab SGN 68 alvespimycin 67 subcutaneous methylnaltrexone 67 superficial bladder cancer 67 CLARITY study 67 phase IIa clinical 67 metastatic colorectal carcinoma 67 docetaxel Taxotere ® 67 Acute Decompensated Heart Failure 67 registrational Phase 67 recurrent NSCLC 67 relapsing multiple sclerosis 67 prostate carcinoma 67 Enzastaurin 67 Vidaza ® 67 postoperative chemotherapy 67 metastatic HRPC 67 Phase #b/#a clinical 67 gemcitabine Gemzar ® 67 Bayer HealthCare Onyx Pharmaceuticals 67 BRIM2 67 NSABP B 67 antiretroviral naïve 67 oral rivaroxaban 67 thetreatment 67 gemcitabine carboplatin 67 lymphoid malignancies 67 Proellex TM 67 metastatic hormone refractory 67 MGd 67 trastuzumab Herceptin ® 67 Edge STudy 67 CAMMS# 67 haematologic 67 XL# SAR# 67 null responder HCV 66 dyskinetic 66 Soft Tissue Sarcoma 66 refractory chronic lymphocytic 66 Pemetrexed 66 demonstrated antitumor activity 66 ELACYT 66 Phase Ib IIa 66 PI3K/Akt pathway inhibitor 66 assessing T DM1 66 HeFH 66 CALGB # [002] 66 polyarticular 66 Phase IIb III 66 multicenter randomized controlled 66 HIV HCV coinfected 66 chemoradiotherapy 66 unresectable tumors 66 hereditary deficiency 66 lenalidomide Revlimid R 66 rALLy clinical trial 66 lymphomas leukemias 66 PSMA ADC 66 fosbretabulin 66 estramustine 66 nab paclitaxel 66 underwent surgical resection 66 complement inhibitor eculizumab 66 recurrent GBM 66 retinal vein occlusion induced 66 IMPACT DCM 66 steroid refractory 66 relapsed Hodgkin lymphoma 66 TASKi3 66 ExTRACT TIMI 66 nonmetastatic 66 ENESTnd 66 Phase Ib clinical 66 Pivotal Phase III 66 systemic anaplastic large 66 Overactive Bladder OAB 66 refractory metastatic colorectal cancer 66 prospective nonrandomized 66 forodesine 66 TG MV 66 either acutely decompensated 66 Omacetaxine 66 Ribavirin causes 66 undergoing elective percutaneous 66 treatment naïve genotype 66 Kit CD# positive 66 alfa 2a 66 irinotecan cisplatin 66 NMIBC 66 unstable angina UA 66 metastatic neuroendocrine tumors 66 weekly subcutaneous injections 66 heavily pretreated 66 Glioblastoma Multiforme 66 de novo kidney transplant 66 refractory acute myeloid 66 blinded randomized placebo controlled 66 systemic ALCL 66 HGS ETR1 mapatumumab 66 carcinoma HCC 65 randomized controlled multicenter 65 PROSTVAC ® 65 glucocorticoid induced osteoporosis 65 severe hepatic dysfunction 65 deep venous thromboses 65 pain palliation 65 AA Amyloidosis 65 refractory colorectal cancer 65 leukemia AML 65 Hormone Refractory Prostate Cancer 65 chronic myocardial ischemia 65 morphometric vertebral fractures 65 LUX Lung 65 Cutaneous T 65 targeting miR 65 oral ridaforolimus 65 acute myeloid 65 refractory myeloma 65 multicenter prospective 65 phase III ACCLAIM 65 landmark ATHENA 65 ACTEMRA TM 65 metastatic renal cell 65 imatinib therapy 65 relapsed refractory AML 65 CIMZIA ™ 65 neovascular form 65 PRIMO CABG 65 oropharyngeal candidiasis OPC 65 achieved CCyR 65 erlotinib Tarceva ® 65 paclitaxel Taxol R 65 refractory ovarian cancer 65 refractory CTCL 65 refractory cutaneous T 65 Genasense ® 65 tumors GIST 65 venous stasis ulcers 65 myocardial infarction ventricular fibrillation 65 TTF Therapy 65 cervical lymph nodes 65 Adjuvant chemotherapy 65 AKT inhibitor 65 Severe Sepsis 65 opioid induced bowel dysfunction 65 Heterozygous Familial Hypercholesterolemia 65 immunomodulatory agents 65 neurogenic bladder 65 riociguat 65 atypical Hemolytic Uremic Syndrome 65 recurrent metastatic ovarian cancer 65 toenail onychomycosis 65 BCIRG 65 receiving chemoradiation therapy 65 intravascular hemolysis 65 refractory NSCLC 65 mRCC 65 Ophena TM 65 sorafenib Nexavar 65 thymoma 65 rALLy 65 Doxil ® 65 Randomized Phase II 65 fallopian tube carcinoma 65 patientswith 65 HCV SPRINT 65 angiographic outcomes 65 overactive bladder syndrome 65 huN# DM1 65 anthracycline taxane 65 verteporfin 65 cilengitide 65 somatostatin analog 65 lung esophageal 65 mg administered orally 65 paclitaxel cisplatin 65 intravenous belinostat 65 Sudhir Agrawal D.Phil 65 FOLFOX6 chemotherapy regimen 65 rheumatoid arthritis psoriatic arthritis 65 Xelox 65 q8h 65 EGFR expressing mCRC 65 ZOLINZA 65 multicentric 65 acyclovir Lauriad R 65 taxane resistant 65 medically refractory 65 RSD# oral 65 including eniluracil ADH 65 PAOD 65 Hodgkin lymphoma HL 65 budesonide foam 65 lung pancreatic 65 platinum refractory 65 hoFH 65 gastrointestinal stromal tumor GIST 65 oral diclofenac 65 evaluating REVLIMID 65 Unstable Angina 65 treat benign prostatic 65 huC# DM4 64 peripheral arterial occlusive disease 64 BR.# 64 aflibercept VEGF Trap 64 infliximab monotherapy 64 underwent resection 64 neurologic progression 64 neoadjuvant 64 benign prostatic hyperplasia enlarged 64 Val HeFT 64 advanced hepatocellular carcinoma 64 recurrent herpes labialis 64 gefitinib Iressa 64 hepatic metastases 64 papillary carcinoma 64 dose escalation phase 64 visceral metastases 64 castrate resistant prostate cancer 64 peritoneal cancer 64 Cloretazine ® 64 Phase IIIb study 64 Intervention Effectiveness 64 rituximab refractory 64 CLL SLL 64 hyperplasia BPH 64 Folfox 64 receptor tyrosine kinase inhibitor 64 anterior uveitis 64 histologically proven 64 Brentuximab Vedotin SGN 64 Subgroup analysis 64 refractory CLL 64 diabetic neuropathic pain 64 ADVANCE PD 64 trial evaluating PRX# 64 prostate cancer CaP 64 dacarbazine DTIC 64 Refractory Hodgkin Lymphoma 64 RCW breast cancer 64 MEND CABG 64 EGFR mutation positive 64 Hepatocellular Carcinoma HCC 64 number NCT# ClinicalTrials.gov 64 pancreatic colon 64 pancreatic adenocarcinoma 64 EXPLORE Xa 64 RECORD1 64 minimally symptomatic 64 cisplatin chemotherapy 64 non valvular atrial 64 STRIDE PD 64 Phase 1b clinical trials 64 opioid naive 64 VELCADE melphalan 64 Proxinium TM 64 SNT-MC#/idebenone 64 Targretin capsules 64 RE LY ® 64 refractory metastatic 64 advanced metastatic renal 64 acute promyelocytic leukemia APL 64 metastatic colorectal 64 relapsed ovarian cancer 64 prostate cancer HRPC 64 PLX STROKE targeting 64 evaluating Xcytrin 64 phase IIb trial 64 icatibant 64 chronic thromboembolic pulmonary 64 dasatinib Sprycel ® 64 REMINYL ® 64 MIST II 64 Intravenous immunoglobulin 64 unresectable liver cancer 64 HGS# 64 radiotherapy RT 64 CHAMPION PCI 64 Aflibercept 64 YONDELIS 64 methotrexate therapy 64 Advanced Melanoma 64 plus dexamethasone 64 acute GvHD 64 multicenter randomized placebo controlled 64 metastatic renal cell carcinoma 64 chronic ITP patients 64 previously untreated follicular 64 abacavir lamivudine 64 noninfectious uveitis 64 AVN# Phase 64 stage IIIB 64 KRAS mutant tumors 64 PEGINTRON REBETOL combination 64 prospective multicenter 64 interferon gamma 1b 64 basal cell carcinoma BCC 64 relapsed CLL 64 metastatic bone 64 severe oral mucositis 64 unfractionated heparin UFH 64 mapatumumab 64 KRAS mutations occur 64 interferon alpha IFN 64 taxane chemotherapy administered 64 de novo AML 64 reduce serum phosphate 64 Augment Injectable 64 Zenvia ™ 64 Tarceva TM 64 paclitaxel eluting stents 64 Chronic lymphocytic leukemia 64 intestinal metaplasia 64 receiving XGEVA 64 liver resection 64 DEB# 64 pulmonary infiltrates 64 Oral Fingolimod 64 Relapsing Remitting Multiple Sclerosis 64 Platinol ® cisplatin 64 relapsed ALL 64 CARE HF 64 docetaxel chemotherapy 64 mitoxantrone plus 64 metastatic castration resistant 64 GEM OS1 64 GEM OS2 64 chronic GVHD 64 mg/m2 cohort 64 Cloretazine R 64 IFN alfa 64 invasive candidiasis 64 TroVax ® 64 concurrent chemoradiation 64 CHOP chemotherapy 64 asymptomatic metastatic 64 Phase III randomized controlled 64 idiopathic thrombocytopenic purpura ITP 64 non splenectomized 64 Dupuytren Disease 64 anastrazole 64 Bronchiectasis 64 Cimzia ® certolizumab pegol 64 HER2 positive metastatic 63 adult chronic ITP 63 intravesical infusion therapy 63 chemotherapy cisplatin 63 Aplidin 63 hemodynamically significant 63 prostate cancer CRPC 63 paclitaxel poliglumex 63 Squamous 63 ALA PDT 63 Patients Treated With 63 opioid induced constipation OIC 63 essential thrombocythemia ET 63 induced macular edema 63 dirucotide MBP# 63 adjuvant cisplatin 63 pediatric neuroblastoma 63 gemcitabine chemotherapy 63 Toxicities 63 EDEMA3 trial 63 colorectal liver metastases 63 vidofludimus 63 exocrine pancreatic insufficiency EPI 63 TMC# C# 63 esophageal candidiasis 63 Coronary Artery Bypass Graft 63 R lenalidomide 63 cyclophosphamide doxorubicin vincristine 63 post herpetic neuralgia PHN 63 Major Depressive Disorder MDD 63 J Am Coll 63 randomized multicenter trial 63 histologic subtype 63 sunitinib Sutent 63 denileukin diftitox 63 multicentre randomized 63 nucleoside naive 63 uremic pruritus 63 multiple myeloma MM 63 Adjunctive 63 ongoing Phase 1b 63 invasive lobular carcinoma 63 osteoporotic vertebral compression fractures 63 carboplatin paclitaxel 63 alpha1 antitrypsin deficiency 63 operable breast cancer 63 unstable angina pectoris 63 develop HBV reactivation 63 evaluating Prochymal 63 epirubicin cyclophosphamide 63 radiation chemoradiation 63 elacytarabine 63 hyperphenylalaninemia HPA due 63 remission induction 63 duplex ultrasonography 63 decompensated liver disease 63 seminoma 63 hepatic arterial 63 Idiopathic Pulmonary Fibrosis 63 NCCTG N# 63 sunitinib malate 63 trials RCTs 63 evaluating picoplatin 63 LymphoStat B belimumab 63 Relapsed Multiple Myeloma 63 axitinib 63 localized renal 63 neoadjuvant treatment 63 hepatorenal syndrome 63 acute mania 63 omega interferon 63 Prostate AdenoCarcinoma Treatment 63 investigational monoclonal antibody 63 Gleevec resistant 63 Sipuleucel T 63 ABCSG 63 capecitabine Xeloda R 63 FASLODEX 63 palliative radiotherapy 63 EOquin TM 63 refractory indolent non 63 Radical prostatectomy 63 HBeAg negative 63 chronic myeloid 63 phase Ib 63 Acute Myeloid Leukaemia AML 63 ToGA 63 IL# PE#QQR 63 ANCA associated 63 phase Ib clinical 63 undergone radical prostatectomy 63 TORISEL 63 metastatic androgen independent 63 rFVIIa 63 medically inoperable 63 evaluating mipomersen 63 pancreatic prostate 63 doxorubicin cyclophosphamide 63 HYVET 63 #mg BID [001] 63 lumiliximab 63 evaluating Actimmune 63 J Am Acad 63 PCI ExTRACT TIMI 63 metastatic CRC 63 ORENCIA ® 63 eribulin mesylate 63 randomized Phase III 63 RoACTEMRA 63 COU AA 63 interferon ribavirin 63 constipation predominant irritable bowel 63 AML MDS 63 relapsed mantle 63 malignant neoplasms 63 transarterial 63 hormone refractory metastatic prostate 63 CINQUIL 63 Cloretazine 63 spinal metastases 63 autoantibody positive 63 headache nasopharyngitis 63 acute leukemias 63 NATRECOR ® 63 Aplidin R 63 placebo controlled Phase III 63 recurrent glioblastoma multiforme GBM 63 Castration Resistant Prostate Cancer 63 telaprevir dosing 63 painful diabetic neuropathy 63 dilated cardiomyopathy DCM 63 CIPN 63 postsurgical pain 63 phase IIIb 63 Myelodysplastic Syndrome MDS 63 VEGFR2 inhibitor 63 ancrod 63 indolent follicular non 63 Randomized controlled 63 miconazole Lauriad ® 63 cell lymphoma CTCL 63 EURIDIS 63 VNP#M 63 cystoid macular edema 63 lymphocytosis 63 Multicenter 63 vinorelbine tartrate 63 R vitespen 63 confirmatory clinical 63 lymphocytic leukemia 63 paclitaxel carboplatin 63 NP2 Enkephalin 63 cutaneous T 63 Phase 2b kidney transplant 63 IIa clinical trials 63 SUTENT ® 63 resistant hormone refractory 63 elevated transaminases 63 MELAS 63 leiomyomas 63 anti angiogenic agents 63 OvaRex ® MAb 63 multicenter placebo controlled 63 fibrotic disease 63 Degarelix 63 IIb clinical trial 63 IBS C 63 cancer mCRC 63 metastatic renal 63 malignant ascites 63 Diabetic Macular Edema 63 noninvasive outpatient 63 pediatric pontine glioma 63 GW# [003] 63 PERSEUS 63 UPLYSO 63 myelodysplastic myeloproliferative diseases 63 nonalcoholic steatohepatitis NASH 63 prokinetic agent 63 desvenlafaxine succinate 63 colorectal carcinoma 63 IMPACT DCM clinical 63 paliperidone ER 63 salmeterol fluticasone 63 R sorafenib tablets 63 Refractory Angina 63 ductal adenocarcinoma 63 SSc 63 metastatic RCC 63 symptomatic carotid stenosis 63 naive HCV 63 Bezielle 63 peritumoral brain edema 63 symptomatic paroxysmal AF 63 cytoreduction 63 recurrent genital herpes 63 allogeneic hematopoietic stem cell 63 Group RTOG 63 BCG refractory carcinoma 63 PROSTVAC VF 63 CURE AF 63 Paroxysmal Nocturnal Hemoglobinuria PNH 63 tumor xenograft models 63 advanced metastatic prostate 63 non resectable 63 primary immunodeficiency PI 63 pancreatic carcinoma 63 Allovectin 7 ® 63 undergoing hematopoietic stem 63 cisplatin resistant 62 oral Janus kinase 62 PFO migraine 62 orally inhaled migraine 62 Atypical Hemolytic Uremic Syndrome 62 adjuvant GIST 62 Hedgehog Pathway Inhibitor 62 dalteparin 62 histologically confirmed 62 CIMZIA TM 62 #I TM# 62 smoldering multiple myeloma 62 postherpetic neuralgia PHN 62 visilizumab 62 biologic DMARD 62 irinotecan containing 62 HER2 positive metastatic breast 62 humanised monoclonal antibody 62 Safinamide 62 intracerebral hemorrhage ICH 62 Surgical resection 62 XIENCE V demonstrated 62 brivanib 62 #rd Annual CTRC 62 brivaracetam 62 sunitinib Sutent ® 62 ischemic cardiomyopathy 62 refractory anaplastic astrocytoma 62 metaglidasen 62 Cimzia TM 62 randomized multicenter Phase III 62 chronic HCV 62 radiochemotherapy 62 symptomatic intracranial 62 benign prostatic hypertrophy BPH 62 dyslipidemia hypertension diabetes 62 ThermoDox R 62 Chronic Heart Failure 62 levodopa induced 62 plus prednisone 62 resected pancreatic cancer 62 pertuzumab 62 Golimumab 62 metastatic adenocarcinoma 62 lexidronam injection 62 tramiprosate Alzhemed TM 62 intravitreal insert 62 IMPACT DCM trial 62 polycythemia vera essential thrombocythemia 62 Nexavar tablets 62 moderate renal impairment 62 FOLOTYN ® 62 immunocompetent patients 62 orally administered inhibitor 62 refractory AML 62 nonrandomized 62 acetonide FA 62 adriamycin 62 relapsed MCL 62 LymphoStat B TM 62 FUSILEV enhances 62 urothelial carcinoma 62 metastatic uveal melanoma 62 adjuvant radiation 62 commercialize deforolimus 62 Dacogen injection 62 relapsed multiple myeloma 62 Albuferon TM 62 lenalidomide dexamethasone 62 Gemzar ® 62 ribavirin RBV 62 Acute Ischemic Stroke 62 DCVax ® Brain 62 HuMax EGFr 62 ATACAND 62 superficial basal cell carcinoma 62 Quinamed 62 transthyretin TTR mediated amyloidosis 62 Sapacitabine 62 BoNTA 62 oral prodrug 62 acute HAE attacks 62 EVEREST II 62 Afatinib 62 TASKi2 62 Novo TTF 62 immunocompetent adults 62 antibody MAb 62 nonsmall cell lung cancer 62 Aryplase 62 prospective randomized controlled 62 sarcoma melanoma 62 II Clinical Trial 62 comparing XIENCE V 62 EchoCRT 62 liver metastasis 62 IIa trial 62 Tectin TM 62 venlafaxine XR 62 esophagogastric 62 thyroid carcinoma 62 bone marrow reticulin deposition 62 TTR amyloidosis 62 DAPT 62 MEND CABG II 62 Advaxis Phase 62 BEXXAR Therapeutic Regimen 62 GOUT 62 sorafenib tablets 62 TO AVOID PREGNANCY WHILE 62 drug eluting stent implantation 62 ovarian endometrial 62 leukemia CLL 62 antiangiogenic therapy 62 liposomal doxorubicin 62 Inhaled nitric oxide 62 familial amyloidotic polyneuropathy FAP 62 Arch Intern Med 62 Chronic Myelogenous Leukemia CML 62 Accelerated Partial Breast Irradiation 62 Evoltra ® 62 Diabetic Macular Edema DME 62 Cariprazine 62 leukemia APL 62 intravesical 62 nodal metastasis 62 juvenile idiopathic arthritis 62 evaluating satraplatin 62 Arch Surg 62 SNT MC# 62 8mg/kg 62 T1c 62 Abdominal ultrasound 62 davunetide intranasal AL 62 ritonavir boosted 62 carcinoma mCRC 62 ADVEXIN therapy 62 oral methylnaltrexone 62 AVOREN 62 aerosolized KL4 surfactant 62 MALT lymphoma 62 clinically localized prostate 62 Mg Usa 62 #mg ATC 62 non resectable metastatic 62 intradermal injections 62 non hodgkin lymphoma 62 Phase 2b Study 62 indolent NHL 62 Virulizin ® 62 irinotecan chemotherapy 62 Acute Exacerbations 62 anti angiogenic therapy 62 receiving VELCADE 62 hematopoietic cancers 62 PEGINTRON TM 62 neovascular diseases 62 refractory prostate cancer 62 VP# [004] 62 oral JAK#/JAK# inhibitor 62 calcineurin inhibitor 62 Myocardial Infarction Study 62 eritoran 62 colorectal adenocarcinoma 62 rhIGF-I/rhIGFBP-3 62 ara C 62 Pharmacokinetics PK 62 hypercholesterolemic patients 62 Stage IIB 62 FOLFOX6 62 Cannabinor 62 BrachySil TM 62 Cell Lymphoma 62 prospective multicenter randomized 62 liposomal amphotericin B 62 multicenter randomized clinical 62 Temsirolimus 62 Phase 1a clinical 62 INTEGRILIN R 62 sodium thiosulfate STS 62 prospective multicenter study 62 PNP inhibitor 62 ribavirin therapy 62 Relapsed Refractory 62 PRIMO CABG2 62 Pivotal Clinical Trial 62 Nilotinib 62 urothelial cancer 62 EGFR expressing 62 Xeloda capecitabine 62 colesevelam HCl 62 idiopathic thrombocytopenic purpura 62 refractory multiple myeloma 62 docetaxel Taxotere R 62 allogeneic bone marrow 62 ER CHOP 62 Glioblastoma Multiforme GBM 62 HCV NS5B polymerase 62 EXJADE 62 Patients Receiving 62 IV metastatic melanoma 62 anthracyclines taxanes 62 placebo controlled dose escalation 62 AEG# 62 Amrubicin 62 dasatinib Sprycel 62 untreated metastatic melanoma 62 choroidal vasculopathy 62 multicenter Phase III 62 FluCAM arm 62 Pegylated Interferon 62 vincristine doxorubicin 62 pegylated interferon peg IFN 62 Kamada AAT 62 trastuzumab DM1 T DM1 62 Phase 1b clinical 62 apoptosis inducer 62 5 fluorouracil leucovorin 62 poststroke depression 62 prostate TURP 62 Vascugel ® 62 Phase IIIb 62 r hGH 62 sacral nerve stimulation 62 osteoid osteoma 62 mycophenolate mofetil 62 Coronary artery bypass graft 62 afatinib 62 enzastaurin 62 #mg QD [001] 62 lymphoma CTCL 62 retrospective cohort study 62 rufinamide 62 alkylating agent 62 hypereosinophilic syndrome 62 TNF antagonist 62 adrenocortical cancer 62 cutaneous melanoma 62 Acute Coronary Syndromes ACS 62 rituximab refractory follicular 62 steroid refractory GvHD 62 unresectable Stage III 62 induced oral mucositis 62 Randomized Phase 62 thorough QT 62 SPRYCEL ® 62 Erythropoietic therapies may 62 occlusion CRVO 62 Budesonide foam crofelemer 62 multicenter clinical 62 prospective randomized multicenter 62 chronic idiopathic thrombocytopenic purpura 62 viral kinetics 62 intravenous RSD# 62 ® lenalidomide 62 potentially hepatotoxic 62 resistant ovarian cancer 62 daily subcutaneous injections 62 REVIVE Diabetes 62 EndoTAGTM 1 62 Infusion Reactions Severe 62 locoregional 62 K ras mutations 62 erythema nodosum 62 Prospective Randomized 62 Peginterferon alfa 2b 62 amrubicin 62 non squamous 62 CCyR 62 basal bolus regimen 62 vapreotide acetate 62 Phase IIa trial 62 acute STEMI 62 Neulasta R 62 low dose cytarabine 62 gastrointestinal stromal 62 Kahalalide F 62 PCNSL 62 osteoporotic compression fractures 62 macular edema secondary 62 immune thrombocytopenic purpura ITP 62 myelofibrosis MF 62 Tumor Response 62 recurrent bladder 62 telaprevir dosed 62 TAXUS VI 62 CA9 SCAN 62 CR nPR 62 prospective multicentre 62 Azedra 62 dose cohort 62 Raptiva ® 62 AERx ® 62 pheochromocytoma 62 Ceplene/IL-2 62 Recurrent Glioblastoma 62 mg/m2 dose 62 R Saizen R 62 Mitomycin C 62 Diffuse Large B 62 dose dose escalation 61 plus methotrexate 61 myeloproliferative disorders 61 FOLFOX chemotherapy 61 CTAP# Capsules 61 gemcitabine Gemzar 61 paroxysmal nocturnal hemoglobinuria PNH 61 deferiprone 61 taxane therapy 61 Acute Myeloid Leukemia AML 61 achieved sustained virologic 61 bladder ovarian 61 Waldenstrom macroglobulinemia 61 teriflunomide 61 hypervascular tumors 61 Randomized Double blind 61 prospectively stratified 61 Panzem R NCD 61 non metastatic osteosarcoma 61 sorafenib Nexavar ® 61 cyclophosphamide chemotherapy 61 Platinol ® 61 EGFr expressing metastatic colorectal 61 Fibrillex TM 61 relapsed leukemia 61 fistulizing Crohn disease 61 metastatic ocular 61 adecatumumab 61 thromboembolic complications 61 Rheos System 61 Juvenile Idiopathic Arthritis 61 bronchogenic carcinoma 61 NeuroStar TMS Therapy 61 ENDEAVOR IV 61 weekly intravenous infusions 61 invasive aspergillosis 61 Ophena 61 mildly symptomatic 61 olaparib 61 AVERROES 61 recurrent squamous cell carcinoma 61 Certolizumab pegol 61 bendamustine 61 Fondaparinux 61 atherothrombotic events 61 de novo coronary 61 metastatic lung cancer 61 pulmonary metastasis 61 constipation OIC 61 Hsp# Inhibitor 61 dosing cohorts 61 biochemical relapse 61 proctitis 61 adjuvant radiotherapy 61 INS# [001] 61 Prednisone Against Refractory 61 Romidepsin 61 unresectable locally advanced 61 everolimus eluting stents 61 thalidomide Thalomid 61 EmbraceAC 61 HGS ETR2 61 malignant neoplasm 61 Triapine 61 lung cancer NSCLC 61 CTEPH 61 Complicated Skin 61 lumbar disk herniation 61 rindopepimut 61 follicular lymphoma FL 61 schizophrenia CIAS 61 unresectable stage 61 Pyridorin 61 MIVI III 61 Renal Cell Carcinoma RCC 61 postoperative AF 61 Phase III randomized 61 ThermoDox ® clinical 61 Raptiva r 61 skeletal metastases 61 oral mTOR inhibitor 61 post operative ileus 61 FOLFIRI chemotherapy 61 phase IIa 61 gastric adenocarcinoma 61 Lupus Nephritis 61 novel tubulin binding 61 myelofibrosis polycythemia vera 61 calcaneal fractures 61 chemotherapy docetaxel 61 irinotecan doxorubicin oxaliplatin paclitaxel 61 initiated Phase Ib 61 surgical debulking 61 carcinoid tumors 61 Neoadjuvant 61 CBLC#